Browse CD8A

Summary
SymbolCD8A
NameCD8a molecule
Aliases CD8; CD8 antigen, alpha polypeptide (p32); T-cell surface glycoprotein CD8 alpha chain; Leu2 T-lymphocyte an ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane Single-pass type I membrane protein. Note=CD8A localizes to lipid rafts only when associated with its partner CD8B. ; SUBCELLULAR LOCATION: Isoform 2: Secreted
Domain PF07686 Immunoglobulin V-set domain
Function

Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class I molecule:peptide complex. The antigens presented by class I peptides are derived from cytosolic proteins while class II derived from extracellular proteins. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. LCK then initiates different intracellular signaling pathways by phosphorylating various substrates ultimately leading to lymphokine production, motility, adhesion and activation of cytotoxic T-lymphocytes (CTLs). This mechanism enables CTLs to recognize and eliminate infected cells and tumor cells. In NK-cells, the presence of CD8A homodimers at the cell surface provides a survival mechanism allowing conjugation and lysis of multiple target cells. CD8A homodimer molecules also promote the survival and differentiation of activated lymphocytes into memory CD8 T-cells.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0007159 leukocyte cell-cell adhesion
GO:0009615 response to virus
GO:0019722 calcium-mediated signaling
GO:0019882 antigen processing and presentation
GO:0019932 second-messenger-mediated signaling
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0042110 T cell activation
GO:0045065 cytotoxic T cell differentiation
GO:0050848 regulation of calcium-mediated signaling
GO:0050850 positive regulation of calcium-mediated signaling
GO:0051607 defense response to virus
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0098542 defense response to other organism
Molecular Function GO:0015026 coreceptor activity
GO:0042287 MHC protein binding
GO:0042288 MHC class I protein binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0042101 T cell receptor complex
GO:0043235 receptor complex
GO:0098552 side of membrane
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
hsa04612 Antigen processing and presentation
hsa04640 Hematopoietic cell lineage
hsa04660 T cell receptor signaling pathway
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Summary
SymbolCD8A
NameCD8a molecule
Aliases CD8; CD8 antigen, alpha polypeptide (p32); T-cell surface glycoprotein CD8 alpha chain; Leu2 T-lymphocyte an ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD8A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD8A and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16899613Bladder carcinomaPromote immunityImmunohistochemical staining for HLA class I, CD4, CD8, CD20, CD68, TIA-1, S-100, and FOXP3 was carried out on specimens from 30 patients who underwent BCG immunotherapy from whom both pretreatment and posttreatment specimens were obtained. Our data show that expression of HLA class I molecules on tumor cells contributes significantly to the therapeutic effect of BCG immunotherapy for bladder cancer. It is suggested that CTLs may be one of main effectors in this therapy.
16882704MelanomaPromote immunityWe found that genetic removal of CTLA-4 induced activation and acquisition of effector functions in pmel-1 CD8 T cells, resulting in the rapid development of severe autoimmune vitiligo. These effects were abrogated by the removal of the CD4 T-cell population. Therefore, we propose that the lack of CTLA-4 on self/tumor antigen–specific CD8 T cells results in autoimmunity and tumor immunity only in the presence of nonspecific, dysregulated CD4 CTLA-4 / T cells.
16849468lymphomaPromote immunityE.G7-OVA growth in the skin was not inhibited in immunodeficient Rag(-/-) or CD8 T cell-deficient mice, suggesting that CD8(+) CTLs mediate tumor elimination. CD8(+) T cell numbers were significantly increased in eyes of mice primed with E.G7-OVA, but few were detected in primary ocular tumors.
Summary
SymbolCD8A
NameCD8a molecule
Aliases CD8; CD8 antigen, alpha polypeptide (p32); T-cell surface glycoprotein CD8 alpha chain; Leu2 T-lymphocyte an ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD8A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD8A
NameCD8a molecule
Aliases CD8; CD8 antigen, alpha polypeptide (p32); T-cell surface glycoprotein CD8 alpha chain; Leu2 T-lymphocyte an ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD8A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.110.871
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0610.971
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1520.913
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5930.358
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.0080.37
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0730.957
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9670.182
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.9840.146
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.090.951
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.3520.142
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6270.506
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4640.0527
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD8A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD8A
NameCD8a molecule
Aliases CD8; CD8 antigen, alpha polypeptide (p32); T-cell surface glycoprotein CD8 alpha chain; Leu2 T-lymphocyte an ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD8A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD8A
NameCD8a molecule
Aliases CD8; CD8 antigen, alpha polypeptide (p32); T-cell surface glycoprotein CD8 alpha chain; Leu2 T-lymphocyte an ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD8A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD8A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD8A
NameCD8a molecule
Aliases CD8; CD8 antigen, alpha polypeptide (p32); T-cell surface glycoprotein CD8 alpha chain; Leu2 T-lymphocyte an ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD8A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD8A
NameCD8a molecule
Aliases CD8; CD8 antigen, alpha polypeptide (p32); T-cell surface glycoprotein CD8 alpha chain; Leu2 T-lymphocyte an ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD8A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD8A
NameCD8a molecule
Aliases CD8; CD8 antigen, alpha polypeptide (p32); T-cell surface glycoprotein CD8 alpha chain; Leu2 T-lymphocyte an ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD8A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD8A
NameCD8a molecule
Aliases CD8; CD8 antigen, alpha polypeptide (p32); T-cell surface glycoprotein CD8 alpha chain; Leu2 T-lymphocyte an ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD8A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.